Phase II
Calithera Biosciences, Inc. announced positive results from its randomized placebo-controlled Phase 2 ENTRATA study of telaglenastat in combination with everolimus in patients with advanced renal cell carcinoma.
Medigene AG announced that clinical data from the interim analysis of the ongoing Phase I / II clinical trial with Medigene’s DC vaccine for the treatment of acute myeloid leukemia was presented during the annual congress of the European Hematology Association taking place from 13 - 16 June in Amsterdam.
KB105 is a new gene therapy candidate engineered with a Transglutaminase-1 (TGM1) gene construct to treat TGM1 deficient autosomal recessive congenital ichthyosis
TLC, announced results from the pre-planned analysis of Part 1 of TLC590’s Phase II clinical trial in patients following bunionectomy.
Pyoderma Gangraenosum is a debilitating, rare autoimmune disease marked by large, painful skin ulcers
Companies from across the globe share business and pipeline updates.
Pharming Group N.V. announces that, following receipt of the Dutch investigating centre’s ethics committee approval, it is commencing a clinical study of the effects of its recombinant human C1 esterase inhibitor (rhC1INH), RUCONEST®, in patients with pre-eclampsia.
Servier and Galapagos NV completed recruitment for their ROCCELLA Phase 2 trial with GLPG1972/S201086, ahead of schedule.
Trial data showed a two-week course delayed the onset of diabetes by as much as two years in clinical patients.
Here’s a look at some of last week’s clinical trial announcements, including some from the American Society of Clinical Oncology Annual Meeting you might have missed.
PRESS RELEASES